HomeCompareTCON vs SPHD

TCON vs SPHD: Dividend Comparison 2026

TCON yields 6211.18% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCON wins by $514736922231177.94M in total portfolio value
10 years
TCON
TCON
● Live price
6211.18%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$514736922231177.94M
Annual income
$498,935,081,000,370,800,000.00
Full TCON calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — TCON vs SPHD

📍 TCON pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCONSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCON + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCON pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCON
Annual income on $10K today (after 15% tax)
$527,950.31/yr
After 10yr DRIP, annual income (after tax)
$424,094,818,850,315,200,000.00/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, TCON beats the other by $424,094,818,850,315,200,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCON + SPHD for your $10,000?

TCON: 50%SPHD: 50%
100% SPHD50/50100% TCON
Portfolio after 10yr
$257368461115588.97M
Annual income
$249,467,540,500,185,400,000.00/yr
Blended yield
96.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TCON right now

TCON
Analyst Ratings
14
Buy
2
Hold
Consensus: Buy
Altman Z
-44.2
Piotroski
6/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCON buys
0
SPHD buys
0
No recent congressional trades found for TCON or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCONSPHD
Forward yield6211.18%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$514736922231177.94M$26.5K
Annual income after 10y$498,935,081,000,370,800,000.00$571.32
Total dividends collected$513674666624982.00M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: TCON vs SPHD ($10,000, DRIP)

YearTCON PortfolioTCON Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$631,818$621,118.01$11,133$432.85+$620.7KTCON
2$37,352,078$36,676,032.53$12,363$450.36+$37.34MTCON
3$2,066,348,794$2,026,382,070.58$13,695$467.39+$2066.34MTCON
4$106,978,454,906$104,767,461,696.78$15,138$483.90+$106978.44MTCON
5$5,183,619,185,269$5,069,152,238,519.27$16,697$499.88+$5183619.17MTCON
6$235,102,301,025,325$229,555,828,497,087.03$18,382$515.31+$235102301.01MTCON
7$9,981,906,672,630,884$9,730,347,210,533,788.00$20,198$530.17+$9981906672.61MTCON
8$396,781,870,195,426,800$386,101,230,055,711,700.00$22,157$544.46+$396781870195.40MTCON
9$14,768,075,916,642,124,000$14,343,519,315,533,017,000.00$24,266$558.18+$14768075916642.10MTCON
10$514,736,922,231,177,940,000$498,935,081,000,370,800,000.00$26,536$571.32+$514736922231177.94MTCON

TCON vs SPHD: Complete Analysis 2026

TCONStock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Full TCON Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this TCON vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCON vs SCHDTCON vs JEPITCON vs OTCON vs KOTCON vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.